Breaking News Bar

Business News and Information

PhaseBio plans $43M stock sale

The proceeds will be used by the Malvern biopharmaceutical company to advance both its lead new drug candidates.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear